 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...206207208209210211212213214215216...235236» |
- napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Jul 14, 2015
P1, N=144, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Jun 2015 --> Dec 2015
- Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jul 14, 2015
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Aug 2015 --> Dec 2015
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2015
P2, N=45, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Jul 13, 2015
P2, N=0, Withdrawn, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Aug 2015 --> Dec 2015 N=100 --> 0
- || New P2/3 trial: PACHA-01: Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Jul 10, 2015
P2/3, N=220, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Avastin (bevacizumab) / Roche
Trial termination, Metastases: Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Jul 9, 2015
P2, N=80, Terminated, Sponsor: HaEmek Medical Center, Israel
N=100 --> 0 Not yet recruiting --> Terminated; No satisfactory acrual
- Enrollment open, Surgery, Metastases: CAOAROAIO-12: Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jul 8, 2015
P2, N=304, Recruiting, Sponsor: Prof. Dr. med. Claus R
Not yet recruiting --> Terminated; No satisfactory acrual Not yet recruiting --> Recruiting
- Enrollment open: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 6, 2015
P2, N=112, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 6, 2015
P2, N=134, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, onartuzumab (RG3638) / Roche
Trial completion, Trial primary completion date, Metastases: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2015
P2, N=194, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Oct 2014
- Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 2, 2015
P2, N=128, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Feb 2014
- || dilpacimab (ABT-165) / AbbVie
Enrollment change, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Jul 1, 2015
P1, N=100, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Feb 2014 N=75 --> 100
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
New trial, Surgery: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) - Jul 1, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Seoul National University Hospital
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial: FOXAGAST: NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma (clinicaltrials.gov) - Jul 1, 2015
P2, N=55, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- || Erbitux (cetuximab) / Eli Lilly
New P3 trial, Metastases: ERMES: Erbitux MEtastatic Colorectal Cancer Strategy Study (clinicaltrials.gov) - Jun 30, 2015
P3, N=600, Recruiting, Sponsor: Carlo Barone
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Jun 29, 2015
P2, N=25, Recruiting, Sponsor: howard safran
N=75 --> 100 Trial primary completion date: Jun 2015 --> Mar 2017
- |||| Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: TAILOR: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (clinicaltrials.gov) - Jun 29, 2015
P3, N=503, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Jun 2015 --> Mar 2017 Trial primary completion date: Jun 2015 --> Nov 2015
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 29, 2015
P1, N=251, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Jun 26, 2015
P1, N=45, Active, not recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2016
- | rosmantuzumab (OMP-131R10) / Mereo Biopharma
New P1 trial, Combination therapy, Metastases: A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 (clinicaltrials.gov) - Jun 26, 2015
P1, N=50, Active, not recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
- | Stivarga (regorafenib) / Bayer
Enrollment closed, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Jun 26, 2015
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- || gedatolisib (PF-05212384) / Celcuity
Trial primary completion date, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 25, 2015
P2, N=190, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2017 --> Mar 2016
- methotrexate IV / Generic mfg., daunorubicin / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 25, 2015
P2, N=163, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Mar 2017 --> Mar 2016 Active, not recruiting --> Completed
- | Removab (catumaxomab) / NeoPharm, Trion Pharma
Enrollment closed, Trial primary completion date: Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (clinicaltrials.gov) - Jun 24, 2015
P2, N=42, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015
- leucovorin calcium / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Surgery: Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer (clinicaltrials.gov) - Jun 23, 2015
P2, N=39, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015 Active, not recruiting --> Completed
- leucovorin calcium / Generic mfg.
Trial suspension: A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) - Jun 20, 2015
P2, N=192, Suspended, Sponsor: University of Arkansas
Active, not recruiting --> Completed Recruiting --> Suspended
- | Vectibix (panitumumab) / Amgen
New P2 trial: The VALENTINO study: Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) (clinicaltrials.gov) - Jun 20, 2015
P2, N=224, Not yet recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 20, 2015
P3, N=350, Active, not recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Recruiting --> Suspended Recruiting --> Active, not recruiting
- imalumab (BAX069) / Takeda, Vectibix (panitumumab) / Amgen
Enrollment open: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 19, 2015
P2, N=90, Recruiting, Sponsor: Baxalta US Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date, Metastases: Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 17, 2015
P2, N=61, Active, not recruiting, Sponsor: Pancreatic Cancer Research Team
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2015
- dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Jun 16, 2015
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2015 Trial primary completion date: May 2015 --> May 2016
- Enrollment closed, Surgery: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Jun 15, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting
- Trial primary completion date, Metastases: NabucCO: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=114, Recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Jul 2015
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=24, Recruiting, Sponsor: Prism Pharma Co., Ltd.
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Apr 2015 --> Mar 2016
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: Apr 2015 --> Mar 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- Trial primary completion date, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Jun 11, 2015
P2, N=100, Recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jun 2015 --> Dec 2016
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jun 2015 --> Dec 2016 Trial primary completion date: May 2015 --> Nov 2015
- Trial primary completion date: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Jun 11, 2015
P2, N=31, Recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: May 2015 --> Nov 2015 Trial primary completion date: Jun 2014 --> Jun 2016
- Trial primary completion date: Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=2, Terminated, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Mar 2013 --> Mar 2016
- Farydak (panobinostat) / Secura Bio
Trial primary completion date, Metastases: Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy (clinicaltrials.gov) - Jun 11, 2015
P1, N=7, Terminated, Sponsor: University of Southern California
Trial primary completion date: Mar 2013 --> Mar 2016 Trial primary completion date: Jun 2015 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: CEBIFOX: Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=59, Active, not recruiting, Sponsor: Martin Schuler, Prof. Dr. med.
Trial primary completion date: Jun 2015 --> Dec 2014 Trial primary completion date: Mar 2015 --> Dec 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: PePiTA: Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=135, Recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- peripheral blood stem cell transplantation / National Cancer Institute
Clinical: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=85, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- methotrexate IV / Generic mfg.
Trial termination, Trial primary completion date, Adverse events: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? (clinicaltrials.gov) - Jun 11, 2015
P2, N=34, Terminated, Sponsor: University College, London
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2015; Recruitment almost complete, has been slow and challenging
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial termination, Combination therapy, Metastases: PEPCOL: Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=55, Terminated, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2015; Recruitment almost complete, has been slow and challenging Suspended --> Terminated; efficacy interim analysis as per protocol
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial termination, Trial primary completion date, Surgery: Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=100, Terminated, Sponsor: National Cancer Institute (NCI)
Suspended --> Terminated; efficacy interim analysis as per protocol Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006
- || prexasertib (ACR-368) / Acrivon Therap
Enrollment change, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jun 11, 2015
P1, N=115, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006 N=70 --> 115
- Enrollment change: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=65, Recruiting, Sponsor: Washington University School of Medicine
N=70 --> 115 N=41 --> 65
- ||| Zydelig (idelalisib) / Gilead
New P1 trial, Combination therapy, Metastases: Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Not yet recruiting, Sponsor: Gilead Sciences
- |||||| Vectibix (panitumumab) / Amgen
Enrollment open: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jun 10, 2015
P3, N=800, Recruiting, Sponsor: Takeda
N=41 --> 65 Not yet recruiting --> Recruiting